Paul Allen offers $300M for brain research; Prometheus patent case stirs a storm in biopharma;

Tools

 @FierceBiotech: Whooping cough bug evades vaccine in Australia. Story | Follow @FierceBiotech

 @JohnCFierce: 7-4 favorable vote at ODAC for Talon's Marqibo hardly a ringing endorsement. Is it good enough? Release | Follow @JohnCFierce

 @RyanMFierce: Addex Therapeutics came out today with positive Phase IIa data for Parkinson's drug supported by MJF Foundation. Release | Follow @RyanMFierce

@MarkHFierce: Embryonic stem-cell research is under fire at U-M, The Detroit Free Press reports. Perplexing. Piece | Follow @MarkHFierce

> Paul Allen has contributed $300 million of his Microsoft fortune to the cause of brain research. The money goes to the Allen Institute for Brain Science, which he founded more than 8 years ago. "As someone who has been touched by the impact of a neurodegenerative disease--my mother has Alzheimer's--there's both a fascination in basic research and the hope that we can move things forward," Allen said. Story

> The Supreme Court's decision to invalidate a pair of patents for Prometheus Labs' diagnostic tests has stirred up a storm in the biopharma industry. The justices said they didn't believe any company could tie up rights related to the laws of nature. But industry officials countered that without diagnostic patents, the court was hobbling the development of personalized meds. Story

> Albany Molecular Research has announced plans to close a facility in Budapest, Hungary, axing 100 jobs in the process. The contract research group/manufacturer says it plans to complete a restructuring in the second quarter. Story

> Coronado Biosciences inked a collaboration deal with Dr. Falk Pharma GmbH and OvaMed GmbH for the development of TSO--Trichuris suis ova or CNDO-201--for Crohn's disease. Release

Pharma News

 @FiercePharma: Sandoz morphine mislabeling prompts urgent notice. News | Follow @FiercePharma

> Study: No reason teens can't buy emergency contraception OTC. More

> Health Canada tells hospitals to quarantine morphine from Sandoz. Story

> Is Watson poised to grab Actavis? Article

> Paper: Merck KGaA won't resort to massive layoffs to trim German workforce. Item

> Is AZ aiming for a Forest buy? More

Vaccines News

> DNA melanoma vaccine shows hope in early studies. Item

> iBio shares jump with flu shot clinical trial. More

> TB vaccine in South African trials; blueprint will drive development. Article

> ImmunoCellular licenses new ovarian cancer target. Story

CRO News

> FSP outsourcing approach remains in demand. More

> Novartis chief touts new effort to offer streamlined, consumer-friendly trials. Story

> inVentiv grabs Kforce's clinical research staff biz for $50M. News

> CRO lobby steps up social media outreach on YouTube. Article

Manufacturing News

> GSK to invest more than £500 million in new manufacturing in U.K. Story

> Nobilus Poland plant gets import ban after FDA warning. News

> Sandoz finds outside suppliers for drugs in shortage. Article

> Explosion, fire at Teva's Pliva plant turns deadly. More

And Finally… Culling data from dozens of heart drug studies, investigators say that daily use of aspirin is linked with a significant reduction in the risk of cancer death. Story